Sökning: "Pricing of Pharmaceuticals"

Hittade 5 avhandlingar innehållade orden Pricing of Pharmaceuticals.

1. 1. Parallel Trade, Reference Pricing and Competition in the Pharmaceutical Market: Theory and Evidence

   Författare :Miyase Yesim Köksal-Ayhan; Göteborgs universitet; []
   Nyckelord :SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; parallel trade; pharmaceuticals; price competition; reference pricing; therapeutic competition; moral hazard; EU enlargement.;

   Sammanfattning : Paper I. Reference Pricing: Making Parallel Trade in Pharmaceuticals Work This paper shows that parallel trade makes pharmaceutical manufacturers reduce their prices in the home (importing) country more when it is combined with the healthcare reimbursement policy of reference pricing, requiring consumers to pay the full extra cost if they don’t buy cheaper parallel imported drugs. LÄS MER

3. 2.

   Författare :Klas Bergenheim; Nationalekonomiska institutionen; []
   Nyckelord :SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; ekonometri; Nationalekonomi; economic policy; economic systems; economic theory; econometrics; Economics; toxikologi; farmaci; Pharmaceutical R D; Patents; Pricing of Pharmaceuticals; Real Options; Pharmacological sciences; pharmacy; pharmacognosy; toxicology; farmakognosi; Farmakologi; ekonomisk teori; ekonomiska system; ekonomisk politik;

   Sammanfattning : The first paper, Pharmaceutical R&D: a real option approach, considers the process of pharmaceutical R&D analyzed with real option theory. This process is analyzed as an opportunity to research and develop a new pharmaceutical. Contrary to other models using real option analysis I use an option that takes time to exercise. LÄS MER

4. 3. Swedish Pharmaceutical Benefit Reforms ?Analyses of implementation, pharmaceutical sales patterns and expenditures

   Författare :Karolina Andersson; Göteborgs universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmaceutical policy; health care reform; reimbursement; co-payment; reference-based pricing; generic substitution; drug cost; cost sharing;

   Sammanfattning : Background: Over the last few decades, the sales of prescription drugs have increased dramatically in many western countries; however, this increase requires individuals and society to bear larger economic consequences. To improve cost control for pharmaceuticals, several reforms attempt to reconcile the economic responsibility of the patients, prescribers and third party payers. LÄS MER

5. 4. Asymmetric Information and The Production of Health

   Författare :Mattias Lundbäck; Nationalekonomiska institutionen; []
   Nyckelord :SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; ekonomisk teori; ekonometri; Nationalekonomi; economic policy; economic theory; economic systems; Economics; econometrics; reimbursement; health care; moral hazard; quality; asymmetric information; ekonomiska system; ekonomisk politik; Hospital science and management; Sjukhusforskning; sjukhusförvaltning; Pharmacological sciences; pharmacognosy; pharmacy; toxicology; Farmakologi; farmakognosi; farmaci; toxikologi;

   Sammanfattning : The common theme of this thesis is the analysis of asymmetric information when applied to the market for health care production. The thesis consists of six more or less independent papers and an introduction to the thesis were purpose and methodology are stated (part one). Part two is an investigation into the pricing of pharmaceuticals in Sweden. LÄS MER

7. 5. Competition and innovation in the Swedish pharmaceutical market

   Författare :Mats Ekelund; Handelshögskolan i Stockholm; []
   Nyckelord :SAMHÄLLSVETENSKAP; SOCIAL SCIENCES;

   Sammanfattning : This thesis consists of four essays in economics related to the pharmaceutical market. The first essay, Pharmaceutical Pricing in a Regulated Market, compares the pricing of new pharmaceuticals in the Swedish market where prices are regulated, with the results of Lu and Comanor who studied the pricing of new pharmaceuticals in the US market. LÄS MER